- Home
- SAMG vs IPHA Comparison
SAMG vs IPHA Comparison
Compare SAMG & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAMG
- IPHA
- Stock Information
- Founded
- SAMG 2002
- IPHA 1999
- Country
- SAMG United States
- IPHA France
- Employees
- SAMG N/A
- IPHA N/A
- Industry
- SAMG Investment Managers
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- SAMG Finance
- IPHA Health Care
- Exchange
- SAMG Nasdaq
- IPHA Nasdaq
- Market Cap
- SAMG 155.5M
- IPHA 160.1M
- IPO Year
- SAMG 2013
- IPHA 2019
- Fundamental
- Price
- SAMG $16.54
- IPHA $1.91
- Analyst Decision
- SAMG
- IPHA Strong Buy
- Analyst Count
- SAMG 0
- IPHA 1
- Target Price
- SAMG N/A
- IPHA $11.50
- AVG Volume (30 Days)
- SAMG 37.3K
- IPHA 15.1K
- Earning Date
- SAMG 03-06-2025
- IPHA 03-27-2025
- Dividend Yield
- SAMG 4.89%
- IPHA N/A
- EPS Growth
- SAMG 4.17
- IPHA N/A
- EPS
- SAMG 1.00
- IPHA N/A
- Revenue
- SAMG $123,651,000.00
- IPHA $20,831,349.00
- Revenue This Year
- SAMG $8.52
- IPHA $220.44
- Revenue Next Year
- SAMG $3.95
- IPHA $81.85
- P/E Ratio
- SAMG $16.36
- IPHA N/A
- Revenue Growth
- SAMG 5.32
- IPHA N/A
- 52 Week Low
- SAMG $13.93
- IPHA $1.29
- 52 Week High
- SAMG $19.20
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- SAMG 40.86
- IPHA 46.68
- Support Level
- SAMG $15.97
- IPHA $1.78
- Resistance Level
- SAMG $16.68
- IPHA $2.03
- Average True Range (ATR)
- SAMG 0.37
- IPHA 0.09
- MACD
- SAMG 0.02
- IPHA -0.02
- Stochastic Oscillator
- SAMG 43.51
- IPHA 50.89
About SAMG Silvercrest Asset Management Group Inc.
Silvercrest Asset Management Group Inc is a wealth management firm focused on providing financial advisory and related family office services to ultra-high net-worth individuals and institutional investors. It advises clients on traditional investment strategies focused on equities, fixed income and cash as well as non-traditional investment strategies including hedge funds, private equity funds, real estate and commodities. It also provides clients with family office services and related administrative services, which include financial planning, tax planning and preparation, partnership accounting and fund administration, and consolidated wealth reporting. The company derives revenues principally from assets under management.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.